ESCRO Committee meetings are held on the first Thursday
of each month. The deadline to submit a protocol for review
is the 3rd Wednesday of the preceding month.
All ESCRO applications are now being processed and tracked using the Human Research Protections Program (HRPP) electronic system.
To submit a new, continuing, or amended protocol for ESCRO Committee review and, when applicable, for Institutional Review Board review:
- Complete and save to your computer these two forms:
Log in to e-IRB Services:
- To upload the forms for an existing protocol choose "My Protocols at a Glance"
- To upload the forms for a new protocol choose "Submit a new project description online"
- Follow the instructions
If you have any questions, contact email@example.com or call
- All research with human embryonic stem cells (hESCs) or human induced pluripotent stem cells (hiPSCs) must be compliant with the UCSD Guidelines for Human Embryonic Stem Cell Research.
- See Protocol Approvals for a checklist of required approvals. There is no fixed sequence in which approvals must be requested, but research is not approved to begin until approvals have been obtained from all appropriate offices.
ESCRO and IRB protocol approvals are for one year from the date of review.
Renewal: To avoid a lapse in approval, a renewal application must be submitted prior to expiration of the current approval. Any project that has expired before a renewal application has been submitted will be closed.
Expired project approval: Under California and Federal regulations, if project approval has expired, then work on the project must be stopped until a new protocol has been reviewed and approved.
Amendments: Any modifications/changes in a project including adding additional cell lines or proposing additional testing must be received and approved by the ESCRO Committee (and the IRB, as appropriate) BEFORE they are initiated except where necessary to eliminate the apparent immediate hazard to subjects. Requests for approval of modifications/changes may be submitted at any time by the Principal Investigator (PI) during the active, approved period of a study.